Select Bibliography

Filter by any of these (after searching):

Atherton, Pamela J

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 27 items

Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)

Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012

Manuscript - Primary - Primary - Symptom Inter - N0993

Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA

Atherton, Pamela J. , Halyard, Michele Y. , Sloan, Jeff A. ... - - Support Care Cancer - 2013

Manuscript - Secondary - Primary - Symptom Inter - N00CA

The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591)

Atherton, Pamela J. , Watkins-Bruner, Deborah W. , Gotay, Carolyn ... - - J Pain Symptom Manage - 2015

Manuscript - Primary - Primary - Health Outcomes - N0591

Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992)

Atherton, Pamela J , Burger, Kelli N , Pederson, Levi D ... - - Clin Trials - 2016

Manuscript - Primary - Primary - Health Outcomes - N0992

Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)

Barton, Debra L. , Shuster, Lynne T. , Dockter, Travis ... - - Support Care Cancer - 2018

Manuscript - Secondary - Primary - Symptom Inter - N10C1

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T. , Gill, Paula ... - - Support Care Cancer - 2018

Manuscript - Primary - Primary - Symptom Inter - N10C1

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Barton, Debra L. , Soori, Gamini S. , Bauer, Brent A. ... - - Support Care Cancer - 2010

Manuscript - Primary - Primary - Symptom Inter - N03CA

A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance)

Barton, Debra L , Atherton, Pamela J , Satele, Daniel V , Qin, Rui ... - - Support Care Cancer - 2020

Manuscript - Primary - Primary - Symptom Inter - NCCTG-N07C4

Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

Barton, Debra L , Wender, Donald B , Sloan, Jeff A , Dalton, Robert J ... - - J. Natl. Cancer Inst. - 2007

Manuscript - Primary - Primary - Symptom Inter - NCCTG-N02C3

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017

Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcomes - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70501 , CALGB-70604 , CALGB-80405 , CALGB-90401

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Kearns, Ann E. , Northfelt, Donald W. , Dueck, Amylou C. ... - - Support Care Cancer - 2010

Manuscript - Primary - Primary - Symptom Inter - N01C8

NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study

Leal, Alexis D. , Qin, Rui , Atherton, Pamela J. , Haluska, Paul ... - - Cancer - 2014

Manuscript - Primary - Primary - Symptom Inter - N08CA

Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA

Martenson, James A. , Halyard, Michele Y. , Sloan, Jeff A. ... - - J Clin Oncol - 2008

Manuscript - Primary - Primary - Symptom Inter - N00CA

Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase 3 Double-Blind, Randomized Trial from the North Central Cancer Treatment Group N06C4

Miller, Robert C. , Schwartz, David J. , Sloan, Jeff A. ... - - Int J Radiat Oncol Biol Phys - 2011

Manuscript - Primary - Primary - Symptom Inter - N06C4

Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)

Neben-Wittich, Michelle A. , Atherton, Pamela J. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2011

Manuscript - Secondary - Primary - Symptom Inter - N06C4

Electronic Patient-Reported Outcomes and Toxicities During Radiotherapy for Head and Neck Cancer

Niska, Joshua R. , Halyard, Michele Y. , Tan, Angelina D. ... - - Qual Life Res - 2017

Manuscript - Secondary - Primary - Health Outcomes - NCCTG-892052

NCCTG N10C2 (Alliance) – A Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes

Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - - Menopause - 2015

Manuscript - Primary - Primary - Symptom Inter - N10C2

NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Symptom Inter - N10C2

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Rosenberg, Jonathan E. , Ballman, Karla A. , Halabi, Susan ... - - J Clin Oncol - 2021

Manuscript - Primary - Primary - GU - CALGB-90601

Repeated Measures Analyses of Dermatitis Symptom Evolution in Breast Cancer Patients Receiving Radiotherapy in a Phase 3 Randomized Trial of Mometasone Furoate vs Placebo (N06C4 [Alliance])

Sio, Terence T. , Atherton, Pamela J. , Birckhead, Brandon J ... - - Support Care Cancer - 2016

Manuscript - Secondary - Primary - Symptom Inter - N06C4

Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial

Sio, Terence T. , Atherton, Pamela J. , Pederson, Levi D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2019

Manuscript - Primary - Primary - Symptom Inter - MC1221

A pilot, randomized trial of daily lisinopril vs placebo to prevent radiation-induced pulmonary distress (Alliance MC1221)

Sio, Terence T. , Atherton, Pamela J. , Zhen, W. Ken ... - IASLC (WCLC) - - 2017

Abstract - Primary - Primary - Symptom Inter - NCT01880528

A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)

Thanarajasingam, Gita , Atherton, Pamela J. , Novotny, Paul J. ... - - Lancet Oncol. - 2016

Manuscript - Secondary-not-in-original - Primary - Health Outcomes - N9741 , NCCTG-97-92-54

Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617

Thanarajasingam, Gita , Dueck, Amylou , Novotny, Paul J. ... - ICML - Hematol Oncol - 2017

Abstract - Primary - Primary - Health Outcomes - A151617 , CALGB-50401

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance)

Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020

Manuscript - Primary - Primary - Health Outcomes - A151617 , CALGB-50401

Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.

Zimmerman, Collin Thomas , Atherton, Pamela J. , Pachman, Deirdre R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Primary - Symptom Inter - NCT01611155

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

Zimmerman, Collin , Atherton, Pamela J. , Pachman, Deirdre ... - - Support Care Cancer - 2016

Manuscript - Primary - Primary - Symptom Inter - NCT01611155